<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>RAPID: Collaborative Research: Enabling the Development of COVID-19 Vaccines, Therapeutics and Diagnostics through Innovations in Measurement Science</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>05/01/2020</AwardEffectiveDate>
<AwardExpirationDate>04/30/2021</AwardExpirationDate>
<AwardTotalIntnAmount>50000.00</AwardTotalIntnAmount>
<AwardAmount>50000</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Prakash Balan</SignBlockName>
<PO_EMAI>pbalan@nsf.gov</PO_EMAI>
<PO_PHON>7032925341</PO_PHON>
</ProgramOfficer>
<AbstractNarration>This broader impacts of this proposed RAPID proposal is to provide critically enabling measurement science tools to government, industry and academic professionals engaged in mitigating the effects of COVID-19 through work from the NSF Industry-University Cooperative Research Center for Bioanalytic Metrology (CBM). Researchers at Indiana University have developed unique instrumentation to determine the composition of very large particles such as viruses, and they will characterize viruses, vaccine candidates, and antibodies bound to viral particles. Making this unique instrumentation generally available to researchers working on COVID-19 vaccines across the national network of government, industry and academic researchers will quickly address the measurement science problems that will inevitably arise during the race to develop a safe and reproducible vaccine. In parallel, the CBM will address challenges of rapid antibody tests that are not quantitative nor highly sensitive, and typical lab-based methods for determining antibody concentrations are long and cumbersome. Researchers at the University of Notre Dame and Purdue University will develop devices to rapidly quantify the amount of COVID-19 antibodies in patient serum. Such analyses are vital for low-cost examination of antibody levels (and hence immunity) over time. The proposed devices will exploit a combination of innovative antibody capture technology developed at Notre Dame, which provides enhanced signals, and Purdue Universityâ€™s expertise in the development of point-of-care diagnostic devices. These measurements will be important for investigating the problem of fading immunity and determining if convalescent plasma from a given patient is appropriate for therapeutic studies.  &lt;br/&gt;&lt;br/&gt;The proposed RAPID research aims to provide fundamental knowledge of the structure of COVID-19 and its elicited antibody response. Analytical and measurement science support of vaccine and biomolecular therapeutic research is notoriously difficult. The molecules in question are often too big and complex for standard characterization methods, and many questions about heterogeneity, stoichiometry and structure cannot easily be answered. Researchers will use advancements in Charge Detection Mass Spectrometry (CDMS) and Ion Mobility Spectrometry (IMS) to study the heterogeneity, stoichiometry, structure and interactions of viral protein assemblies and to provide essential measurements for characterizing newly developed vaccine and therapeutic candidates for COVID-19. The CDMS and IMS tools at the CBM are unique and will allow researchers to directly observe inactivated viruses, 'dummy' viral particles without nucleic acids, bioconjugates containing immunogens on a hapten carrier, oligonucleotides, antibodies complexed to target proteins, and antibodies bound to viral particles. These instruments are starting to revolutionize the analysis of bioconjugations, vaccine development, gene therapies and protein therapeutics. Development of devices for rapidly examining antibody titer will rely on antibody capture in porous membranes that have a long pathlength for sensitive optical detection and a high surface area to volume ratio that enables efficient antibody capture. Device design will exploit expertise in the development of thin strip microfluidic diagnostics. Based on the fluorescence intensity of captured secondary antibodies, these devices will provide a measure of the abundance of different classes of COVID-19 antibodies.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>05/01/2020</MinAmdLetterDate>
<MaxAmdLetterDate>05/01/2020</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2031090</AwardID>
<Investigator>
<FirstName>Merlin</FirstName>
<LastName>Bruening</LastName>
<PI_MID_INIT>L</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Merlin L Bruening</PI_FULL_NAME>
<EmailAddress>mbruenin@nd.edu</EmailAddress>
<PI_PHON>5173033192</PI_PHON>
<NSF_ID>000398841</NSF_ID>
<StartDate>05/01/2020</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>University of Notre Dame</Name>
<CityName>NOTRE DAME</CityName>
<ZipCode>465565708</ZipCode>
<PhoneNumber>5746317432</PhoneNumber>
<StreetAddress>940 Grace Hall</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>Indiana</StateName>
<StateCode>IN</StateCode>
<CONGRESSDISTRICT>02</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>IN02</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>824910376</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>UNIVERSITY OF NOTRE DAME DU LAC</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM>048994727</ORG_PRNT_DUNS_NUM>
</Institution>
<Performance_Institution>
<Name><![CDATA[University of Notre Dame]]></Name>
<CityName>Notre Dame</CityName>
<StateCode>IN</StateCode>
<ZipCode>465565708</ZipCode>
<StreetAddress><![CDATA[940 Grace Hall]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Indiana</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>02</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>IN02</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>1662</Code>
<Text>PFI-Partnrships for Innovation</Text>
</ProgramElement>
<ProgramElement>
<Code>5761</Code>
<Text>IUCRC-Indust-Univ Coop Res Ctr</Text>
</ProgramElement>
<ProgramReference>
<Code>096Z</Code>
<Text>COVID-19 Research</Text>
</ProgramReference>
<ProgramReference>
<Code>7914</Code>
<Text>RAPID</Text>
</ProgramReference>
<Appropriation>
<Code>0120</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2020~50000</FUND_OBLG>
<POR>
<DRECONTENT><![CDATA[<div class="porColContainerWBG"> <div class="porContentCol"><p>This collaborative research included unprecedented characterization of virus structures (Indiana University), exploration of the capture and detection of anti-SARS-CoV-2 antibodies in serum and plasma in a single-step colorimetric assay (Purdue University), and development of a 5-min assay for a SARS-CoV-2 antibody (University of Notre Dame).&nbsp; This report describes the research performed at Notre Dame.&nbsp; Quantitation of antibodies in human serum or plasma is important for monitoring antibody therapies, assessing immune responses, and screening of donor serum for convalescent serum therapy.&nbsp;</p> <p>The research created an antibody assay that relies on flow of human serum through glass-fiber filters at the bottom of the wells in a 96-well plate.&nbsp; Modification of the filters with a SARS-CoV-2 protein (specifically the receptor binding domain of the spike protein) enables selective capture of an anti-spike protein antibody in &lt;1 min during passage of serum through a filter.&nbsp; Subsequent binding of a fluorescently labelled secondary antibody to the captured anti-spike antibody leads to a fluorescence signal, whose intensity depends on the concentration of the anti-spike antibody in the serum.&nbsp; Figure 1 schematically illustrates the analytical procedure.&nbsp; The entire process of passing the serum through the filter, rinsing, passing the secondary antibody through the filter, rinsing again and reading the fluorescence occurs in &lt;5 min.&nbsp; In contrast most typical quantitative antibody analyses require more than 1 hour.&nbsp; Moreover, many assays can occur in parallel using the different wells of the plate.&nbsp;</p> <p>Calibration curves established from analyses on different days with multiple replicate membranes have small variations and allow determination of antibody levels in &lt;5 min.&nbsp; The assays can occur in diluted or undiluted serum, but dilution is necessary if the antibody levels are high.&nbsp; Moreover, the technique also applies to the analyses of therapeutic antibodies for treating diseases such as cancer.&nbsp;</p> <p>One of the potential applications of quantitative assays for antibodies against the spike protein of SARS-CoV-2 is screening of donor serum for convalescent serum therapy. Studies of COVID-19 neutralization antibodies suggest that the donor cut-off value for antibodies against SARS-CoV-2 is &gt;100 ?g/mL for suitable donor serum. With appropriate dilution, the modified 96-well plates allow determination of such antibody concentrations with an error &lt;30%. Thus, with further work the 96-well plate containing immobilized SARS-CoV-2 protein might serve as a convenient tool for donor screening in convalescent serum therapy. However, thus far the analyses employed a single antibody with high affinity for the RBD protein.&nbsp; Donor antibodies will likely be more difficult to detect due to a range of affinities.</p> <p>Two PhD students who participated in their project are taking positions in the pharmaceutical industry.&nbsp;</p> <p>&nbsp;</p><br> <p>            Last Modified: 07/01/2021<br>      Modified by: Merlin&nbsp;L&nbsp;Bruening</p> </div> <div class="porSideCol"> <div class="each-gallery"> <div class="galContent" id="gallery0"> <div class="photoCount" id="photoCount0">          Image         </div> <div class="galControls onePhoto" id="controls0"></div> <div class="galSlideshow" id="slideshow0"></div> <div class="galEmbox" id="embox"> <div class="image-title"></div> </div> </div> <div class="galNavigation onePhoto" id="navigation0"> <ul class="thumbs" id="thumbs0"> <li> <a href="/por/images/Reports/POR/2021/2031090/2031090_10667554_1625143838027_graphicforoutcomescropped--rgov-214x142.jpg" original="/por/images/Reports/POR/2021/2031090/2031090_10667554_1625143838027_graphicforoutcomescropped--rgov-800width.jpg" title="Workflow for Antibody Analysis"><img src="/por/images/Reports/POR/2021/2031090/2031090_10667554_1625143838027_graphicforoutcomescropped--rgov-66x44.jpg" alt="Workflow for Antibody Analysis"></a> <div class="imageCaptionContainer"> <div class="imageCaption">Figure 1.  Scheme of capture of a SARS-CoV-2 antibody using a membrane with immobilized SARS-CoV-2 protein, and subsequent binding of a labelled secondary antibody to create a fluorescent signal and determine the SARS-CoV-2 antibody concentration.</div> <div class="imageCredit">Merlin L. Bruening</div> <div class="imagePermisssions">Royalty-free (unrestricted use)</div> <div class="imageSubmitted">Merlin&nbsp;L&nbsp;Bruening</div> <div class="imageTitle">Workflow for Antibody Analysis</div> </div> </li> </ul> </div> </div> </div> </div>]]></DRECONTENT>
<POR_COPY_TXT><![CDATA[ This collaborative research included unprecedented characterization of virus structures (Indiana University), exploration of the capture and detection of anti-SARS-CoV-2 antibodies in serum and plasma in a single-step colorimetric assay (Purdue University), and development of a 5-min assay for a SARS-CoV-2 antibody (University of Notre Dame).  This report describes the research performed at Notre Dame.  Quantitation of antibodies in human serum or plasma is important for monitoring antibody therapies, assessing immune responses, and screening of donor serum for convalescent serum therapy.   The research created an antibody assay that relies on flow of human serum through glass-fiber filters at the bottom of the wells in a 96-well plate.  Modification of the filters with a SARS-CoV-2 protein (specifically the receptor binding domain of the spike protein) enables selective capture of an anti-spike protein antibody in &lt;1 min during passage of serum through a filter.  Subsequent binding of a fluorescently labelled secondary antibody to the captured anti-spike antibody leads to a fluorescence signal, whose intensity depends on the concentration of the anti-spike antibody in the serum.  Figure 1 schematically illustrates the analytical procedure.  The entire process of passing the serum through the filter, rinsing, passing the secondary antibody through the filter, rinsing again and reading the fluorescence occurs in &lt;5 min.  In contrast most typical quantitative antibody analyses require more than 1 hour.  Moreover, many assays can occur in parallel using the different wells of the plate.   Calibration curves established from analyses on different days with multiple replicate membranes have small variations and allow determination of antibody levels in &lt;5 min.  The assays can occur in diluted or undiluted serum, but dilution is necessary if the antibody levels are high.  Moreover, the technique also applies to the analyses of therapeutic antibodies for treating diseases such as cancer.   One of the potential applications of quantitative assays for antibodies against the spike protein of SARS-CoV-2 is screening of donor serum for convalescent serum therapy. Studies of COVID-19 neutralization antibodies suggest that the donor cut-off value for antibodies against SARS-CoV-2 is &gt;100 ?g/mL for suitable donor serum. With appropriate dilution, the modified 96-well plates allow determination of such antibody concentrations with an error &lt;30%. Thus, with further work the 96-well plate containing immobilized SARS-CoV-2 protein might serve as a convenient tool for donor screening in convalescent serum therapy. However, thus far the analyses employed a single antibody with high affinity for the RBD protein.  Donor antibodies will likely be more difficult to detect due to a range of affinities.  Two PhD students who participated in their project are taking positions in the pharmaceutical industry.           Last Modified: 07/01/2021       Submitted by: Merlin L Bruening]]></POR_COPY_TXT>
</POR>
</Award>
</rootTag>
